SCYNEXIS Highlights Promising Antifungal Data at IDWeek Event
SCYNEXIS Showcases SCY-247 at IDWeek 2024
SCYNEXIS, Inc. (NASDAQ: SCYX), a leading biotechnology company focused on addressing drug-resistant and challenging infections, is set to present new and compelling preclinical data on its second-generation antifungal agent, SCY-247, at the highly anticipated IDWeek event in Los Angeles. This event takes place from October 16 to October 19, 2024, offering an opportunity for healthcare professionals, researchers, and industry experts to engage with cutting-edge research.
Presentation Details for SCY-247
The presentations will feature both an oral and a poster session, allowing for comprehensive discussions on the efficacy and pharmacokinetics of SCY-247. Below are the key details:
Oral Presentation Highlights
Title: Efficacy of SCY-247, a Second-generation Triterpenoid Antifungal, in Three Murine Models of Invasive Fungal Infections
Session: Mycology Matters: Insights into Fungal Infections
Date/Time: October 17, 2024, at 10:45 AM PDT
Location: Los Angeles Convention Center, Room 403 B
Presenter: David A. Angulo, M.D., President and CEO of SCYNEXIS
Poster Presentation Insights
Title: SCY-247: A Second-generation IV/Oral Triterpenoid Antifungal with Extensive Tissue Distribution and Pharmacokinetics, and Low Drug-Drug Interaction Potential
Session: New Drug Development
Date/Time: October 18, 2024, from 12:15 PM to 1:30 PM PDT
Location: Los Angeles Convention Center, Halls JK
Presenter: David A. Angulo, M.D., President and CEO of SCYNEXIS
The Promise of SCY-247
SCY-247 represents a significant advancement in the antifungal space, focusing on a novel class of glucan synthase inhibitors known as triterpenoids. This innovative antifungal compound is currently in the pre-IND development stage and aims to address the growing challenge of antimicrobial resistance (AMR) in systemic fungal infections, which can lead to high mortality rates. The triterpenoid class is noteworthy as it is the first new class of antifungal compounds approved since 2001, combining existing glucan synthase inhibition with the flexibility of both oral and intravenous (IV) formulations.
Early studies have demonstrated SCY-247’s broad-spectrum activity against a range of multidrug-resistant fungal pathogens, which is critical in a landscape where treatment options are limited. Additionally, SCYNEXIS is optimistic that the FDA will grant SCY-247 qualified designations for both the IV and oral formulations, acknowledging its potential to make a significant impact in treating these difficult infections.
About SCYNEXIS, Inc.
Founded to innovate the way patients are treated for severe and resistant infections, SCYNEXIS, Inc. (NASDAQ: SCYX) continues to develop its proprietary antifungal platform known as “fungerps.” One of the company's key achievements includes the licensing of ibrexafungerp to GSK, which became the first representative of this class. The FDA approved ibrexafungerp tablets, branded as BREXAFEMME, in June 2021 for vulvovaginal candidiasis, followed by a second indication to reduce recurrent cases. SCYNEXIS remains committed to addressing unmet medical needs with its innovative antifungal agents, including SCY-247, which is currently in preclinical development.
Contact Information for Inquiries
For further information or inquiries, please contact:
Investor Relations
Irina Koffler
LifeSci Advisors
Tel: (646) 970-4681
Email: ikoffler@lifesciadvisors.com
Frequently Asked Questions
What is SCY-247?
SCY-247 is a second-generation antifungal compound developed by SCYNEXIS, designed to target drug-resistant fungal infections.
When and where will SCYNEXIS present data on SCY-247?
SCYNEXIS will present findings at IDWeek 2024 in Los Angeles on October 17 and 18.
Who is presenting the SCY-247 data?
The presentations will be given by David A. Angulo, M.D., the President and CEO of SCYNEXIS.
What are the potential benefits of SCY-247?
It offers broad-spectrum antifungal activity against multidrug-resistant organisms and has low drug-drug interaction potential.
How does SCYNEXIS aim to combat antimicrobial resistance?
By developing innovative antifungal therapies like SCY-247, SCYNEXIS seeks to address the rising challenge of antimicrobial resistance in fungal infections.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Exciting Transformations Await Life Sciences Events in 2025
- Growth and Future of Buy Now Pay Later in U.S. Market
- Empowering Future Leaders: Attend FBLA's Career Conferences
- Cyberimpact Enhances Marketing with New Landing Pages Feature
- Explore Exciting Discounts on Beatbot Pool Cleaning Robots
- Global Demand for Bilevel Positive Pressure Ventilators Rising
- Enhancing Customer Experience Through Innovative Training
- Montage Partners Unveils Revolutionary Montage Accelerate Program
- Transformative Trends Shaping the Future of Medical Device Outsourcing
- Renibus Therapeutics Showcases RBT-1 Innovations at AMCP 2024
Recent Articles
- LeddarTech Innovates Automotive Safety with Cutting-Edge AI
- Fenbo Holdings Reports Strong Financial Performance for H1 2024
- Pacira BioSciences Marks Milestone with New J-Code for EXPAREL
- Carpenter Technology Corporation's Upcoming Earnings Call Insights
- Exploring the Next Big Breakout Restaurant Stocks
- Spectral AI Revolutionizes Wound Care with New Technology
- D-BOX Technologies Announces Departure of Board Member
- How to Enhance Retirement Income with Social Security Strategies
- Exploring Opportunities: CMC Metals' Groundbreaking Projects
- Marjorie Taylor Greene's Strategic Stock Acquisitions Revealed
- Constellation Brands Unveils Strong Second Quarter Results
- FirstService to Reveal Q3 Financial Outcomes Soon
- FTI Consulting's Upcoming Financial Results and Insights
- Employee Election Results for AKVA Group ASA Board Members
- U.S. Economy Demonstrates Strong Resilience Amid Global Challenges
- Nykredit Realkredit A/S Adjusts Coupon Rates on Bonds
- DexCom, Inc. Shareholder Alert: Important Class Action News
- Alphamin Reports Strong Q3 FY2024 Results with Dividend Boost
- Class Action Insights for Extreme Networks Shareholders
- Hellas Gold and Eldorado Gold Support Scholarship for Greek Students
- Arch Biopartners Secures Debt Settlement Through Unit Issuance
- Urgent Update for Investors in Super Micro Computer Stocks
- Costamare Inc. Elects New Class II Directors at Stockholder Meeting
- Acadia Healthcare Faces Securities Investigation and Losses
- Ford Motor Company Faces Legal Challenges: What You Need to Know
- Automotive Collision Repair Market Set for Robust Growth
- Altius Minerals Highlights Q3 2024 Project Generation Growth
- D-BOX Technologies Inc. Board Resignation and Future Steps
- Innovative Digital Solutions Tackling Healthcare Staffing Issues
- Elevai Biosciences Secures New Patents for Innovative Treatment
- IBAT Launches Innovative Loan Marketplace for Community Banks
- Worksport Ltd Expands Government Sales and Sustainable Offerings
- FirstService Corporation Sets Date for Q3 Financial Results
- Howard Hughes Begins New Luxury Project at The Woodlands
- Curaleaf Opens New Dispensary in Florida, Expanding Access
- ZK International Achieves Key Contract to Boost Gas Infrastructure
- Vistra Energy Achieves Higher Stock Target Amid Market Changes
- i3 Verticals' Strategic Shift Boosts Confidence in Future Growth
- New Horizons for 1101 White Cliff with $21 Million Property Deal
- Targa Resources Sees Promising Future with New Projects in 2024
- Elevai Labs Targets Obesity with Innovative EL-22 Patents
- Soligenix and Sterling Pharma Solutions Join Forces for Growth
- Impact of Desktop Metal's Merger Approval on 3D Printing
- September Sees Slight Decrease in Planned US Layoffs Amid Economic Shifts
- Amazon Aims to Recruit 250,000 Workers This Holiday Season
- Truist Adjusts Tesla Price Target Amid Market Changes
- Air France-KLM Implements Strategic Cost-Cutting Measures
- Top Stocks to Consider as S&P 500 Faces Market Resistance
- Market Watch: Economic Focus Amid Mideast Turmoil
- Murphy Oil Corporation Unveils Early Tender Results for Debt